Triumvira

Home - Triumvira Immunologics | Engineered T Cell Therapies

Business Model
B2B
Last Round
Extension RoundMar 2022
Rounds
2

Indexed holds 2 funding rounds and 4 investors for this company. The full record is or through the API.

About

Triumvira is a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer. Its proprietary T cell Antigen Coupler technology is a versatile platform that activates natural T cell functions differently from CAR-T and engineered T cell receptor therapies. The lead clinical candidate, TAC101-CLDN18.2, targets claudin 18.2-positive solid tumors and has shown stronger anti-cancer properties and a more favorable safety profile than CAR-T and standard-of-care therapies in preclinical studies.

Summary

Triumvira is a Biotech company based in Canada. Its most recent funding was an Extension Round in Mar 2022. Investors include B Capital Group, Oceanpine Capital and Northpond Ventures.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundMar 2022

Sign up to see all 2 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Triumvira on Indexed.vc
<a href="https://indexed.vc/companies/triumvira"><img src="https://indexed.vc/api/badge/company/triumvira" alt="Triumvira on Indexed.vc" width="260" height="76" /></a>